Source:http://linkedlifedata.com/resource/umls/id/C0058126
MSH: An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL.,NCI: An enzyme involved in pyrimidine catabolism. Increased DPD levels can influence tumor response to 5-fluorouracil-based chemotherapy through increased inactivation of the agent in tumor cells. Increases of the DPD mRNA level in cancerous tissue seem to reflect tumor progression. High DPD mRNA levels in liver metastasis and advanced colorectal cancer may have clinical importance for 5-fluorouracil-based chemosensitivity. (from Ann Surg Oncol 2002;9:599-603),NCI: The enzyme that catalyzes the initial rate-limiting step in the degradation of endogenous uracil and thymine, and exogenous fluoropyrimidines. Convulsive disorders, motor retardation and mental retardation are the most abundant phenotypes observed in dihydropyrimidine dehydrogenase (DPD) deficient patients; also presents an increased risk of toxicity in cancer patients receiving 5-fluorouracil